NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Forecast, Price & News

$4.93

-0.01 (-0.20%)

(As of 05/31/2023 ET)

Compare

Today's Range: $4.77
▼
$4.99
50-Day Range: $3.59
▼
$6.59
52-Week Range: $3.16
▼
$10.97

Volume: 64,973 shs
Average Volume: 136,882 shs
Market Capitalization: $202.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.75

Acumen Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 219.5% Upside
$15.75 Price Target
Short Interest: Healthy
0.58% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.22
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.30) to ($1.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

331st out of 1,006 stocks

Biological Products, Except Diagnostic Industry

44th out of 167 stocks

3.5

Analyst's Opinion

Consensus Rating
Acumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.75, Acumen Pharmaceuticals has a forecasted upside of 219.5% from its current price of $4.93.
Amount of Analyst Coverage
Acumen Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.58% of the float of Acumen Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acumen Pharmaceuticals has recently decreased by 26.29%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Acumen Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Acumen Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABOS.

2.9

News and Social Media Coverage

News Sentiment
Acumen Pharmaceuticals has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
19 people have searched for ABOS on MarketBeat in the last 30 days.
MarketBeat Follows
Only 4 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Acumen Pharmaceuticals is held by insiders.
Percentage Held by Institutions
67.92% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.30) to ($1.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acumen Pharmaceuticals is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acumen Pharmaceuticals is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acumen Pharmaceuticals has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Acumen Pharmaceuticals (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Stock News Headlines

May 28, 2023 | americanbankingnews.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Down 26.3% in May

May 24, 2023 | americanbankingnews.com

Acumen Pharmaceuticals, Inc. Expected to Post FY2023 Earnings of ($1.13) Per Share (NASDAQ:ABOS)

June 1, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 19, 2023 | americanbankingnews.com

Acumen Pharmaceuticals (NASDAQ:ABOS) Receives New Coverage from Analysts at Cantor Fitzgerald

May 18, 2023 | msn.com

Cantor Fitzgerald Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Overweight Recommendation

May 16, 2023 | finance.yahoo.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript

May 14, 2023 | americanbankingnews.com

Q3 2023 EPS Estimates for Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Increased by Analyst

May 14, 2023 | americanbankingnews.com

Head-To-Head Contrast: Acumen Pharmaceuticals (ABOS) & The Competition

June 1, 2023 | Behind the Markets (Ad)

WARNING to all American Investors

China's sneaky plan could wipe out your retirement - in a single morning. Learn how to protect yourself here>>>

May 12, 2023 | americanbankingnews.com

Short Interest in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Decreases By 63.2%

May 9, 2023 | finanznachrichten.de

Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023 | finance.yahoo.com

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023 | msn.com

Earnings Outlook For Acumen Pharmaceuticals

May 7, 2023 | americanbankingnews.com

Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Tuesday

May 4, 2023 | finance.yahoo.com

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

May 3, 2023 | msn.com

Lilly sends Alzheimer’s drug developers higher after trial data

May 2, 2023 | finance.yahoo.com

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

April 24, 2023 | americanbankingnews.com

Head to Head Review: Acumen Pharmaceuticals (ABOS) versus Its Peers

April 16, 2023 | americanbankingnews.com

Acumen Pharmaceuticals (NASDAQ:ABOS) vs. Cullinan Oncology (NASDAQ:CGEM) Financial Survey

April 15, 2023 | americanbankingnews.com

Acumen Pharmaceuticals (ABOS) and The Competition Head to Head Comparison

April 9, 2023 | finance.yahoo.com

Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the company

April 4, 2023 | americanbankingnews.com

Head to Head Comparison: Acumen Pharmaceuticals (NASDAQ:ABOS) and ZIVO Bioscience (OTCMKTS:ZIVO)

April 3, 2023 | markets.businessinsider.com

BTIG Remains a Buy on Acumen Pharmaceuticals (ABOS)

April 1, 2023 | americanbankingnews.com

Acumen Pharmaceuticals (NASDAQ:ABOS) PT Lowered to $13.00 at Credit Suisse Group

April 1, 2023 | americanbankingnews.com

HC Wainwright Reiterates "Buy" Rating for Acumen Pharmaceuticals (NASDAQ:ABOS)

March 30, 2023 | americanbankingnews.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q1 2023 Earnings of ($0.31) Per Share

March 29, 2023 | seekingalpha.com

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ABOS Company Calendar

Last Earnings: 3/27/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ABOS
CUSIP: N/A
CIK: 1576885
Web: www.acumenpharm.com
Phone: 434-297-1000
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $15.75
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +219.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-42,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.36%
Return on Assets: -22.53%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.41
Quick Ratio: 16.41

Sales & Book Value

Annual Sales: $1.44 million
Price / Sales: 140.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.37 per share
Price / Book: 1.13

Miscellaneous

Outstanding Shares: 41,030,000
Free Float: 39,097,000
Market Cap: $202.28 million
Optionable: Not Optionable
Beta: -1.56

Key Executives

Mr. Daniel J. O'Connell M.B.A. (Age 52)
CEO, Pres & Director
Comp: $801.62k

Mr. Matt Zuga
CFO, Chief Bus. Officer & Corp. Sec.

Dr. Eric Siemers M.D. (Age 68)
Chief Medical Officer
Comp: $460.64k

Mr. Russell Barton M.S. (Age 64)
Chief Operating Officer

Mr. Derek M. Meisner Esq. (Age 52)
J.D., Chief Legal Officer

Ms. Robyn Moxon M.A.
Mang. of Corp. & Clinical Communications

Ms. Julie Bockenstette
Exec. VP & Head of HR

Ms. Siew Tin Gan M.S.
Assistant VP & Head of Clinical Operations

Ms. Janice Hitchcock
VP & Head of Regulatory Affairs

Ms. Liean Schenck M.S.
VP & Head of CMC

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ABOS Stock - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings or view top-rated stocks.
What is Acumen Pharmaceuticals' stock price forecast for 2023?: 4 Wall Street analysts have issued 1 year price targets for Acumen Pharmaceuticals' shares. Their ABOS share price forecasts range from $13.00 to $22.00. On average, they anticipate the company's share price to reach $15.75 in the next year. This suggests a possible upside of 219.5% from the stock's current price.
View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts.
How have ABOS shares performed in 2023?: Acumen Pharmaceuticals' stock was trading at $5.40 at the beginning of the year. Since then, ABOS shares have decreased by 8.7% and is now trading at $4.93.
View the best growth stocks for 2023 here.
Are investors shorting Acumen Pharmaceuticals?: Acumen Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 159,800 shares, a drop of 26.3% from the April 30th total of 216,800 shares. Based on an average daily trading volume, of 168,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.6% of the shares of the company are short sold.
View Acumen Pharmaceuticals' Short Interest.
When is Acumen Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our ABOS earnings forecast.
How were Acumen Pharmaceuticals' earnings last quarter?: Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) released its earnings results on Monday, March, 27th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04.

When did Acumen Pharmaceuticals IPO?: (ABOS) raised $125 million in an IPO on Thursday, July 1st 2021. The company issued 8,333,333 shares at $14.00-$16.00 per share.
What is Acumen Pharmaceuticals' stock symbol?: Acumen Pharmaceuticals trades on the NASDAQ under the ticker symbol "ABOS."
Who are Acumen Pharmaceuticals' major shareholders?: Acumen Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Great Point Partners LLC (2.56%), BlackRock Inc. (1.64%), Commodore Capital LP (0.98%), Hudson Bay Capital Management LP (0.87%), Guardian Point Capital LP (0.32%) and Jane Street Group LLC (0.18%). Insiders that own company stock include John A Stalfort III, Marc Benioff, Nathan B Fountain, Paul B Manning and Sands Capital Global Venture F.
View institutional ownership trends.
How do I buy shares of Acumen Pharmaceuticals?: Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Acumen Pharmaceuticals' stock price today?: One share of ABOS stock can currently be purchased for approximately $4.93.
How much money does Acumen Pharmaceuticals make?: Acumen Pharmaceuticals (NASDAQ:ABOS) has a market capitalization of $202.28 million and generates $1.44 million in revenue each year. The company earns $-42,860,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis.
How can I contact Acumen Pharmaceuticals?: The official website for the company is www.acumenpharm.com. The company can be reached via phone at 434-297-1000 or via email at investors@acumenpharm.com.

This page (NASDAQ:ABOS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial